These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27048339)

  • 1. Selecting Good 'Drug-Like' Properties to Optimize Small Molecule Blood-Brain Barrier Penetration.
    Trippier PC
    Curr Med Chem; 2016; 23(14):1392-407. PubMed ID: 27048339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small molecules as central nervous system therapeutics: old challenges, new directions, and a philosophic divide.
    Banks WA; Greig NH
    Future Med Chem; 2019 Mar; 11(6):489-493. PubMed ID: 30912980
    [No Abstract]   [Full Text] [Related]  

  • 4. Blood-brain barrier permeability considerations for CNS-targeted compound library design.
    Hitchcock SA
    Curr Opin Chem Biol; 2008 Jun; 12(3):318-23. PubMed ID: 18435937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Noncanonical Anionic Peptide That Translocates a Cellular Blood-Brain Barrier Model.
    Neves-Coelho S; Eleutério RP; Enguita FJ; Neves V; Castanho MARB
    Molecules; 2017 Oct; 22(10):. PubMed ID: 29057814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical approaches to evaluating and optimizing brain exposure in early drug discovery.
    Freeman BB; Yang L; Rankovic Z
    Eur J Med Chem; 2019 Nov; 182():111643. PubMed ID: 31514017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the brain uptake and permeability of small molecules through the BBB: A technical overview.
    Chowdhury EA; Noorani B; Alqahtani F; Bhalerao A; Raut S; Sivandzade F; Cucullo L
    J Cereb Blood Flow Metab; 2021 Aug; 41(8):1797-1820. PubMed ID: 33444097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in blood-brain barrier disruption as a CNS delivery strategy.
    Bellavance MA; Blanchette M; Fortin D
    AAPS J; 2008; 10(1):166-77. PubMed ID: 18446517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human ABC transporters at blood-CNS interfaces as determinants of CNS drug penetration.
    Chaves C; Shawahna R; Jacob A; Scherrmann JM; Declèves X
    Curr Pharm Des; 2014; 20(10):1450-62. PubMed ID: 23789951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolutionarily Conserved Roles for Blood-Brain Barrier Xenobiotic Transporters in Endogenous Steroid Partitioning and Behavior.
    Hindle SJ; Munji RN; Dolghih E; Gaskins G; Orng S; Ishimoto H; Soung A; DeSalvo M; Kitamoto T; Keiser MJ; Jacobson MP; Daneman R; Bainton RJ
    Cell Rep; 2017 Oct; 21(5):1304-1316. PubMed ID: 29091768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanodelivery systems for overcoming limited transportation of therapeutic molecules through the blood-brain barrier.
    Kim KT; Lee HS; Lee JJ; Park EK; Lee BS; Lee JY; Bae JS
    Future Med Chem; 2018 Nov; 10(22):2659-2674. PubMed ID: 30499740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
    Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
    Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.
    Stanimirovic DB; Bani-Yaghoub M; Perkins M; Haqqani AS
    Expert Opin Drug Discov; 2015 Feb; 10(2):141-55. PubMed ID: 25388782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crossing the blood-brain barrier with nanoparticles.
    Zhou Y; Peng Z; Seven ES; Leblanc RM
    J Control Release; 2018 Jan; 270():290-303. PubMed ID: 29269142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for transporting nanoparticles across the blood-brain barrier.
    Zhang TT; Li W; Meng G; Wang P; Liao W
    Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
    Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E
    Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tight junction modulation of the blood brain barrier: CNS delivery of small molecules.
    Greene C; Campbell M
    Tissue Barriers; 2016; 4(1):e1138017. PubMed ID: 27141420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood-brain barrier endogenous transporters as therapeutic targets: a new model for small molecule CNS drug discovery.
    Pardridge WM
    Expert Opin Ther Targets; 2015; 19(8):1059-72. PubMed ID: 25936389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.